Table 2. Patients characteristics and treatment response by PIK3CA mutation, copy number variation, PTEN, pAkt, and INPP4B expression.
| All patients | PIK3CA mutation | PIK3CA copy number | PTEN | pAkt | INPP4B | |||||||||||
| WT | Mutationa | P | Normal/loss | Gainb | P | Low | High | P | Low | High | P | Low | High | P | ||
| N | 42 | 36 | 7 | 37 | 6 | 12 | 29 | 10 | 30 | 7 | 32 | |||||
| Mean age | 53.0 | 53.1 | 52.6 | 0.974 | 53.6 | 49.8 | 0.352 | 51.8 | 53.2 | 0.456 | 54.9 | 52.4 | 0.650 | 53.6 | 53.0 | 0.927 |
| Mean tumor size (mm)+SD | 34+16 | 34+17 | 32+12 | 0.843 | 34+16 | 30+19 | 0.344 | 29+13 | 35+18 | 0.295 | 32+16 | 35+17 | 0.839 | 50+24 | 30+13 | 0.035 |
| Nodal status | ||||||||||||||||
| negative | 21 (49%) | 19 (53%) | 2 (29%) | 18 (49%) | 3 (50%) | 6 (50%) | 14 (48%) | 5 (50%) | 15 (50%) | 3 (43%) | 16 (50%) | |||||
| positive | 22 (51%) | 17 (47%) | 5 (71%) | 0.412 | 18 (51%) | 3 (50%) | 0.645 | 6 (50%) | 15 (52%) | 1.00 | 5 (50%) | 15 (50%) | 1.00 | 4 (57%) | 16 (50%) | 1.00 |
| Nuclear grade | ||||||||||||||||
| 1–2 | 24 (57%) | 21 (60%) | 3 (43%) | 22 (59%) | 2 (40%) | 7 (58%) | 15 (54%) | 6 (67%) | 16 (53%) | 1 (14%) | 20 (65%) | |||||
| 3 | 3 (18%) | 14 (40%) | 4 (57%) | 0.438 | 15 (41%) | 3 (60%) | 0.636 | 5 (42%) | 13 (46%) | 1.00 | 3 (33%) | 14 (47%) | 0.704 | 6 (86%) | 11 (35%) | 0.031 |
| ER | ||||||||||||||||
| negative | 23 (53%) | 20 (56%) | 3 (43%) | 19 (51%) | 4 (67%) | 6 (59%) | 16 (55%) | 8 (80%) | 14 (47%) | 3 (43%) | 18 (56%) | |||||
| positive | 20 (47%) | 16 (44%) | 4 (57%) | 0.687 | 18 (49%) | 2 (33%) | 0.669 | 6 (50%) | 13 (45%) | 1.00 | 2 (20%) | 16 (53%) | 0.069 | 4 (57%) | 14 (44%) | 0.682 |
| PR | ||||||||||||||||
| negative | 32 (74%) | 29 (81%) | 4 (57%) | 28 (76%) | 5 (83%) | 8 (67%) | 23 (79%) | 10 (100%) | 21 (70%) | 4 (57%) | 25 (78%) | |||||
| positive | 11 (26%) | 7 (19%) | 3 (43%) | 0.325 | 9 (24%) | 1 (17%) | 1.00 | 4 (33%) | 6 (21%) | 0.441 | 0 (0%) | 9 (30%) | 0.081 | 3 (43%) | 7 (22%) | 0.344 |
| Mean ki67+SD | 44.7+19 | 43+19 | 53+25 | 0.364 | 45+20 | 44+22 | 0.195 | 50+22 | 39+20 | 0.839 | 42+22 | 37+19 | 42+20 | 41+18 | 0.473 | |
| Tumor subtype | ||||||||||||||||
| luminal/HER2 | 19 (44%) | 15 (79%) | 4 (21%) | 20 (54%) | 4 (67%) | 6 (50%) | 17 (59%) | 8 (80%) | 15 (50%) | 3 (43%) | 19 (59%) | |||||
| HER2 | 24 (56%) | 21 (88%) | 3 (13%) | 0.68 | 17 (46%) | 2 (33%) | 0.678 | 6 (50%) | 12 (41%) | 0.734 | 2 (20%) | 15 (50%) | 0.145 | 4 (57%) | 13 (41%) | 0.677 |
| Treatment response | ||||||||||||||||
| pCR | 26 (60%) | 24 (67%) | 2 (29%) | 22 (59%) | 4 (67%) | 4 (33%) | 21 (72%) | 7 (70%) | 17 (57%) | 3 (43%) | 21 (66%) | |||||
| non-pCR | 17 (40%) | 12 (33%) | 5 (71%) | 0.093 | 15 (41%) | 2 (33%) | 1.00 | 8 (67%) | 8 (28%) | 0.034 | 3 (30%) | 13 (43%) | 0.711 | 4 (57%) | 11 (34%) | 0.396 |
WT; wild type, ER; estrogen receptor, PR; progesteron receptor, HER2; human epidermal growth factor 2, PTEN; phosphatase and tensin homolog, INPP4B; inositol polyphosphate 4-phosphatase-II,
a
Mutation was defind as positive if the proportion of mutant DNA was more than 10% by digital PCR analysis.
b
copy number gain was defiend if the copy number of PIK3CA was greater than 1.5 compared to RNaseP.